A phase II study of recombinant interleukin-2 with or without recombinant interferon-beta in non-Hodgkin's lymphoma. A study of the Cancer and Leukemia Group B.
A phase II study of recombinant interleukin-2 with or without recombinant interferon-beta in non-Hodgkin's lymphoma. A study of the Cancer and Leukemia Group B.
复制标题
重组白细胞介素 2 联合或不联合重组干扰素 β 在非霍奇金淋巴瘤中的 II 期研究。
DOI：
10.1097/00002371-199208000-00006
复制
发表时间：
1992
期刊：
影响因子：
--
通讯作者：
Peterson,BA
中科院分区：
文献类型：
--
作者：
Duggan,DB;Santarelli,MT;Zamkoff,K;Lichtman,S;Ellerton,J;Cooper,R;Poiesz,B;Anderson,JR;Bloomfield,CD;Peterson,BA
白细胞介素-2 (IL-2) 和干扰素-β (IFN-β) 已被证明具有抗淋巴恶性肿瘤的活性，这可能是通过增强淋巴因子激活的杀伤 (LAK) 细胞和自然杀伤 (NK) 细胞活性来介导的。体外和体内证据表明IL-2和IFN-β的组合具有协同作用。癌症和白血病 B 组 (CALGB) 对 49 名复发或难治性非霍奇金淋巴瘤 (NHL) 患者进行了一项 IL-2 联合或不联合 IFN-β 的随机 II 期试验。总体毒性很严重，有 17 名患者出现危及生命的毒性。三名患者因治疗相关死亡。七名患者 (17%) 出现缓解。治疗组之间在毒性特征、反应率或体内 NK 和 LAK 活性的调节方面没有显着差异。我们得出的结论是，在本研究中使用的剂量和方案中，IL-2 联合或不联合 IFN-β 都不是治疗 NHL 的有效方法。
Interleukin-2 (IL-2) and interferon-[beta](IFN-[beta]) have demonstrated activity against lymphoid malignancies, presumably mediated by the augmentation of lymphokine-activated killer (LAK) cell and natural killer (NK) cell activity. There is in vitro and in vivo evidence to suggest that the combination of IL-2 and IFN-[beta] is synergistic. The Cancer and Leukemia Group B (CALGB) conducted a randomized phase II trial of IL-2 with or without IFN-[beta] in 49 patients with relapsed or refractory non-Hodgkin's lymphoma (NHL). Overall toxicity was severe, with 17 patients experiencing life-threatening toxicity. Three patients had treatment-related deaths. Responses were noted in seven patients (17%). There were no meaningful differences between treatment arms in toxicity profile, response rate, or modulation of in vivo NK and LAK activity. We conclude that IL-2 with or without IFN-[beta] is not effective therapy for NHL in the doses and schedule used in this study.